Glenmark Pharmaceuticals plans to set up a new manufacturing facility in Monroe Corporate Centre, North Carolina, US. The facility will be spread over 100,000 sq feet and the company will first begin work on an oral solid unit and thereafter set up manufacturing units for injectables and topicals.
Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals said, “The US is a key strategic market for Glenmark and it is important for us to have a manufacturing base here to serve our growing business in the country. Over the next five years, we will make significant investments in this proposed facility and set up three units which will produce oral solids, injectables and topicals,” he added.
The company expects to start manufacturing activity by the end of the current financial year FY 2014 – 15. This facility is dedicated only for the US market and is Glenmark’s first manufacturing facility in North America adding to its list of 14 plants in four countries – India, Brazil, Argentina and Czech Republic.
EP News Bureau– Mumbai